Global Blood Culture Test Market Forecast to Reach $8.94 Billion by 2031

Clinical demand for blood culture testing is intensifying as healthcare systems confront the dual challenges of antimicrobial resistance and a growing burden of bloodstream infections. While traditional culture-based methods remain the primary standard—capturing 72.8% of the market share in 2025—the industry is undergoing a significant shift toward laboratory automation and molecular diagnostics. Hospitals, particularly those managing high-acuity intensive care and oncology units, represent the fastest-growing segment, fueling demand for both automated platforms and the recurring consumables required to support them.

Major diagnostic players are aggressively reshaping their portfolios to capture this shifting demand. Recent high-value transactions, such as the $18.8 billion combination of Waters Corporation and BD’s diagnostics businesses, highlight a broader strategic push toward integrated microbiology workflows. As the market consolidates, with the top five firms controlling approximately 60% of revenue, competition is increasingly focused on the ability to provide faster, AI-enabled identification of pathogens. North America currently leads this technological adoption, supported by robust healthcare expenditure and a well-established infrastructure for advanced infectious disease diagnostics.